BEBT-701
BEBT-701 employs proprietary GDOC technology to target validated genes associated with hypertension (angiotensinogen, AGT) and hyperlipidemia (Proprotein convertase subtilisin/kexin type 9, PCSK9), offering a dual-action therapeutic approach. This innovative design harnesses the synergy of modulating multiple pathways with a single therapeutic molecule. Preclinical studies show that BEBT-701 achieves significantly higher efficacy than single siRNA therapies, with durable effects observed in both rodents and monkeys. Notably, non-GLP toxicity studies demonstrate a favorable safety profile, supporting its potential as a transformative treatment for cardiovascular and metabolic diseases.
Copyright ©2018-2022 Guangzhou BeBetter Medicine Technology Co, LTD.粤ICP备18065301号